Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 13 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma – second-line	Axicabtagene Ciloleucel (Yescarta; KTE-C19)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2019	View \| Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments	Epcoritamab (GEN-3013)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma	Glofitamab (RG-6026)	Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2022	View \| Download
Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma	Lenalidomide (Revlimid) , R-CHOP	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2019	View \| Download
Lisocabtagene Maraleucel (Liso-Cel) for Relapsed/Refractory Diffuse Large B-cell Lymphoma	Lisocabtagene maraleucel (Liso-cel; JCAR017)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2018	View \| Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line	Lisocabtagene maraleucel (Liso-cel; JCAR017)	Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2020	View \| Download
Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line	Loncastuximab Tesirine (ADCT-402; Lonca; Zylonta)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line	Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2020	View \| Download
Polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of diffuse large B-cell lymphoma	Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) , Rituximab (MabThera; Rituxan; RG 105)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2018	View \| Download